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Abstract
Background: The concentrations of hepatitis B virus (HBV) DNA and surface antigen (HBsAg) are two critical virological
variables to be monitored in chronic hepatitis B. HBsAg is derived from the HBV genome. Thus, higher HBV-DNA
concentrations should implicate higher HBsAg levels. Nevertheless, the two variables do not manifest a simple linear
relationship due to elusive host factor involvements. The aim of this study was to address the discrepancy of HBV DNA
and HBsAg levels by a quantitative modeling of HBsAg concentrations.
Methods: Pretreatment hematological, histological and virus serological records of 327 chronic hepatitis B patients
were reviewed. Two independent patient cohorts were used for validation.
Results: Univariate/multivariate analysis showed that ISHAK fibrosis stages, HBV-DNA levels and hepatitis e-antigen status
were independently associated with HBsAg concentrations. In agreement with the natural history of chronic hepatitis B,
HBsAg concentrations were negatively correlated with ISHAK fibrosis stages (adjusted P = 0.002). Subgroup analysis
showed that significant HBsAg-DNA correlation existed in high-viral-titer patients with HBV-DNA > 6 log10 IU/mL (P < 0.
001), but not in low-viral-titer patients with HBV-DNA≤ 6 log10 IU/mL (P = 0.076). A backward stepwise linear regression
analysis in the low-viral-titer subgroup revealed a significant correlation between HBsAg levels and a linear combination
of HBV-DNA levels and platelet counts. A biphasic model was thus established to accommodate patients with high and
low HBV-DNA titers:
HBsAg ¼ 0:538  HBVDNAþ 0:001  platelet  ðj6HBVDNAj þ 6HBVDNAÞ0:321
The estimated HBsAg concentrations correlated well with the measured HBsAg levels not only in the model construction
cohort (N =327, P < 0.001), but also in two validation cohorts comprising respectively the patients who had received
pretreatment liver biopsy assessments (N = 45, P = 0.001), and the treatment-naïve patients who had not received liver
biopsy (N = 80, P < 0.001).
Conclusion: HBsAg concentrations can be quantitatively estimated by viral DNA concentrations and human platelet
counts.
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Background
Chronic hepatitis B virus (HBV) infection is an endemic
disease with a global burden of 350 million patients [1].
This disease persists for multiple decades, and its natural
history comprises the immune tolerance, immune clear-
ance and inactive residual phases [2–6]. During the
chronic infection, episodes of liver inflammation may
occur which cause progressive liver fibrosis and cirrho-
sis, leading toward thrombocytopenia [7], hypoalbumin-
emia [8], portal hypertension, esophageal varices, ascites
[9], liver decompensation and hepatocellular carcinoma
(HCC) [10]. To prevent such devastating consequences,
effective antiviral therapies were now vigorously used,
with viral and host status carefully monitored [11].
Serum concentrations of HBV DNA and surface protein
antigen (HBsAg) are both important viral markers [12].
HBsAg is derived from the HBV genome. Thus, higher
HBV DNA concentrations should implicate higher
HBsAg levels.
Despite the established molecular origin, serum HBV
DNA and HBsAg did not manifested a simple linear re-
lationship in the natural course. The HBV DNA and
hepatitis B e-antigen (HBeAg) levels were drastically re-
duced in the immune clearance phase, while the HBsAg
levels were further reduced continuously in the inactive
residual phase [2–6]. The discrepancy between HBV
DNA and HBsAg levels made them independent vari-
ables rather than confounding variables in clinical stud-
ies. For example, they played different roles in the
prediction of subsequent HCC [13]. Medical guidelines
suggested that anti-viral treatments should be given to
patients in the immune clearance phase for the purpose
of expediting the natural course into the inactive re-
sidual phase; and to patients with viral reactivation dur-
ing the inactive residual phase [11, 12, 14]. HBV DNA
was demonstrated to be effectively suppressed, often to
undetectable levels, by treatments of approved nucltos(-
t)ide analogs including lamivudine [15], adefovir [16],
entecavir [17], telbivudine [18] and tenofovir [19]. The
HBsAg, however, remained positive for years for most of
these treated patients. This was why HBsAg seroconver-
sion (the disappearance of HBsAg and the production of
anti-HBs antibody), rather than the HBV DNA undetect-
ability, was regarded as the closest sign of cure [12]. On
the other hand, patients with negative HBsAg but with
positive HBV DNA were occasionally identified, and re-
ferred to as the occult hepatitis B patients [20–22].
These patients were still at risk of HBV reactivation [22].
The lack of linear relationship between HBV DNA and
HBsAg may be partly explained by the viral life cycle.
The covalently closed circular DNA (cccDNA) is the
template for generating messenger RNAs, which are fur-
ther translated to produce HBsAg, as well as the prege-
nomic RNAs which are reversely transcribed to viral
DNA [23]. Since the HBV DNA can integrate into the
human genome, the HBsAg may also be derived from
the integrated HBV DNA in addition to cccDNA [24].
The viral life cycles occurred in the human hepatocytes,
making them susceptible to host factors.
The discrepancy between serum HBV DNA and HBsAg
levels remained to be quantitatively evaluated. Therefore,
we employed a data-driven approach and conducted a sys-
tematic, multivariate evaluation of hematological, histo-




This study was approved by the institutional review
board of the Chang Gung Memorial Hospital, Taiwan,
and conducted in accordance with the Declaration of
Helsinki. All patients have given informed consent for
the deposition of their clinical samples to the tissue bank
of Chang Gung Memorial Hospital, Taiwan, for aca-
demic researches.
In the first stage, clinical records of 327 chronic hepa-
titis B patients who received pretreatment hematology,
liver histology and viral serology assessments between
years 2007–2009 were retrospectively retrieved for a
quantitative modeling (Table 1). Liver histology was evalu-
ated by the ISHAK hepatic activity indexes [25]. In the
second stage, two independent cohorts were assessed for
the validation purposes. The first cohort comprised 45 pa-
tients who also received liver biopsy for pretreatment eval-
uations between years 2007–2009. The second cohort
comprised 80 anti-hepatitis B treatment-naïve patients
evaluated between years 2010–2012. These patients did
not receive liver biopsy.
Quantitation of HBV DNA and HBsAg concentrations
HBV DNA levels were measured by use of the COBAS
AmpliPrep/COBAS TaqMan HBV Test, v2.0 assay
(Roche Molecular Systems Inc, Pleasanton, CA) accord-
ing to manufacturer’s protocols. HBsAg concentrations
were measured by use of Elecsys HBsAg II assay (Roche
Diagnostics GmbH, Mannheim, Germany).
Statistical analysis
The HBV DNA and HBsAg concentrations were consist-
ently represented here in the logarithm scale due to their
wide numerical ranges. Clinical associations were evalu-
ated by univariate and multivariate linear regressions.
Subgroup analysis was then performed to identify pa-
tient stratum where the significant HBsAg-HBV DNA
correlation was lost. For this subgroup, modulating fac-
tors for the DNA-HBsAg relationships were then evalu-
ated by the backward stepwise linear regression method,
where the F-test were used to evaluate the model
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performance. The modulating factors were then intro-
duced into a prediction model. The statistical analysis
was performed using the SPSS software (IBM, Armonk,
NY). P values smaller than 0.05 were considered statisti-
cally significant.
Results
HBV DNA levels, HBeAg positivity and ISHAK fibrosis
stages were independently associated with HBsAg levels
The first cohort comprised 327 chronic hepatitis B pa-
tients (Table 1). Age, ISHAK fibrosis stages, HBV DNA
levels, hepatitis B e-antigen (HBeAg) positivity, platelet
counts and hemoglobin levels were significantly associ-
ated with HBsAg levels in the univariate analysis
(Table 2). When these variables were entered into multi-
variate analysis, only three variables remained signifi-
cantly associated (ISHAK fibrosis stages, HBV DNA
levels and HBeAg positivity) (Table 2). Among them,
HBV DNA is the most strongly associated variable (P <
0.001). An initial model of HBsAg by use of the three in-
dependent variables was therefore constructed as a
benchmark using the multivariate linear regression as:
HBsAg ¼ 0:274  HBV DNAþ 0:314
 0 if HBeAg negativeð Þ  0:123
 ISHAK fibrosis scoreþ 1:858
The estimated HBsAg levels by the three-variable model
were highly correlated with the measured HBsAg levels
(Pearson’s correlation r = 0.59; P < 0.001). The standard
deviation of the regression residual is 0.79 log10 IU/ml.
Identification of a patient subgroup which lacked
significant HBV DNA-HBsAg correlations
We further conducted the subgroup analysis of patients
stratified by the above three variables. Significant
HBsAg-DNA correlations remained in HBeAg positive
and negative patient subgroups (both P < 0.001), in
ISHAK score ≥ 4 or ≤ 3 subgroups (both P < 0.001), and
in patients with HBV-DNA > 6 log10 IU/mL (P < 0.001).
However, no significant association were found in the
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HBV DNA (log10 IU/ml) 6.35 ± 1.71
HBeAg positive 146 (44.65%)
HBsAg (log10 IU/ml) 3.33 ± 0.98
Table 1 Baseline characteristics of patients in the model
construction cohort (Continued)
Hematology
ALT (IU/L) 177.31 ± 173.34
AST (IU/L) 106.96 ± 122.57
Bilirubin (mg/dL) 0.98 ± 0.42
Albumin (g/dL) 4.55 ± 0.35
Gamma-glutamyltransferase (IU/L) 59.53 ± 46.75
Platelet (1000/mm3) 189.78 ± 50.31
Hemoglobin (g/dL) 15.20 ± 1.36
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patient subgroup with HBV-DNA ≤ 6 log10 IU/mL (Fig. 1).
A baseline comparison of the low- and high- HBV DNA
titer subgroups, defined using the boundary threshold of 6
log10 IU/mL, showed that the low-titer subgroup has a
significantly lower percentage of HBeAg positive patients
(27.48%) than the high-titer subgroup (56.12%, Table 3).
A biphasic model of HBsAg concentrations using platelet
counts and HBV DNA concentrations
A scatter plot was then produced to offer a visualization
of the relationship between the HBV DNA and HBsAg
identified in the previous subgroup analysis (Fig. 2a).
Significant HBsAg-DNA correlation were found in pa-
tients with HBV-DNA > 6 log10 IU/mL but not in pa-
tients with HBV-DNA ≤ 6 log10 IU/mL, suggesting
unknown modulating factors of the HBsAg levels in the
HBV DNA low-titer subgroup. Therefore, a backward
stepwise linear regression analysis was then performed
in the subgroup when HBV-DNA ≤ 6 log10 IU/mL (N =
131). This was done by incorporating all the 16 clinical
variables into a multivariate linear regression equation,
then gradually removing irrelevant variables one at a
Table 2 Association of viral and host variables to quantitative HBsAg concentrations using linear regression
Univariate Analysis Multivariate Analysis
Variables Regression coefficient 95% CI P Adjusted regression coefficient 95% CI P
Age
-0.015 (-0.024 ~ -0.006) 0.002 0.002 (-0.009 ~ 0.013) 0.678
Gender-Male
-0.188 (-0.491 ~ 0.115) 0.224
ISHAK Fibrosis Stages
-0.134 (-0.206 ~ -0.061) <0.001 -0.125 (-0.203 ~ -0.48) 0.002
Piecemeal necrosis
-0.098 (-0.223 ~ 0.038) 0.156
Confluent necrosis
-0.073 (-0.210 ~ 0.064) 0.293
Focal (spotty) lytic necrosis, apoptosis
and focal inflammation
-0.064 (-0.207 ~ 0.078) 0.375
Portal inflammation
-0.083 (0.197 ~ 0.031) 0.152
HBV DNA (log10 IU/ml)
0.310 (0.258 ~ 0.363) <0.001 0.267 (0.197 ~ 0.337) <0.001
HBeAg
0.709 (0.509 ~ 0.909) <0.001 0.301 (0.045 ~ 0.566) 0.021
ALT
0.000 (0.000 ~ 0.001) 0.23
AST
0.001 (0.000 ~ 0.002) 0.144
Bilirubin
-0.121 (-0.372 ~ 0.130) 0.343
Albumin
-0.017 (-0.455 ~ 0.422) 0.94
GGT
-0.002 (-0.006 ~ 0.001) 0.122
Platelet
0.003 (0.001 ~ 0.005) 0.003 0.002 (0.000 ~ 0.005) 0.064
Hemoglobin
-0.107 (-0.204 ~ -0.010) 0.03 -0.57 (-0.137 ~ 0.023) 0.162
Statistical significant values (P <0.05) were now presented in italic font
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time, and evaluating the statistical significance (Fig. 2b).
At the end of the stepwise analysis, the linear combin-
ation of two variables, platelet counts and DNA levels,
was found to be significantly correlated with HBsAg
levels (F-test P = 0.048, degrees of freedom = 2).
We continued to construct a biphasic model of HBsAg
level using (i) HBV-DNA alone when HBV-DNA > 6
log10 IU/mL, and (ii) HBV-DNA and platelet counts to-
gether when HBV-DNA ≤ 6 log10 IU/mL.
HBsAg ¼ 0:538 HBVDNAþ 0:001  platelet
 ðj6HBVDNAj þ 6HBVDNAÞ0:321
Where |‧| represented the absolute-value function.
The relationship between the HBV DNA levels, platelet
counts and the estimated HBsAg levels was visualized
in Fig. 2c. In the model construction cohort, the
HBsAg levels calculated by the biphasic model were
significantly correlated with the measured HBsAg levels
(r = 0.60, P < 0.001). The standard deviation of the re-
gression residual is 0.78 log10 IU/ml.
Clinical records of additional 45 patients with liver
biopsy-included pretreatment evaluations were used for
the first validation (Table 4). Significant positive correla-
tions were found between estimated and measured
HBsAg concentrations (r = 0.47, P = 0.001). The standard
deviation of the residual is 0.82 log10 IU/mL. Further-
more, a cohort of 80 treatment-naïve patients (not re-
ceiving pretreatment liver biopsy) evaluated between
2010-2012 were recruited for the second validation
(Table 5). Significant positive correlations were found
again (r = 0.57, P < 0.001). The standard deviation of the
residual is 0.88 log10 IU/mL. A visual presentation of the
estimated and the measured HBsAg levels in the two
validation cohorts were shown in Fig. 2d.
Discussion
Chronic hepatitis B often lasted for decades, if not life-
time. The HBsAg level was high in the immune toler-
ance phase. It reduced gradually in the immune
clearance phase and the inactive residual phases [12]. A
strong positive linear relationship between age and the
Fig. 1 Pearson’s correlation (r) of HBsAg and HBV DNA levels in patient subgroups stratified by HBeAg status, ISHAK fibrosis stages and HBV
DNA levels
Table 3 Baseline characteristics of patients with HBV DNA below or above 106 IU/mL
HBV DNA Low HBV DNA High P
Subject number 131 196
Age 45.66 ± 11.62 43.24 ± 10.83 0.059
Gender
Male 115 (87.79%) 165 (84.18%) 0.363
Female 16 (12.21%) 31 (15.82%)
Liver Histology
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Table 3 Baseline characteristics of patients with HBV DNA below or above 106 IU/mL (Continued)
ISHAK Fibrosis Stages
0 2 (0.61%) 0 (0%) 0.164
1 15 (11.45%) 25 (12.76%)
2 16 (12.21%) 35 (17.86%)
3 53 (40.46%) 57 (29.08%)
4 11 (8.40%) 22 (11.22%)
5 29 (22.14%) 45 (22.96%)
6 5 (3.82%) 12 (6.12%)
Piecemeal necrosis
0 45 (34.35%) 56 (28.57%) 0.234
1 68 (51.91%) 97 (49.49%)
2 15 (11.45%) 32 (16.33%)
3 3 (2.29%) 11 (5.61%)
Confluent necrosis
0 126 (96.18%) 181 (92.35%) 0.368
1 1 (0.76%) 5 (2.55%)
2 0 (0%) 2 (1.02%)
3 1 (0.76%) 0 (0%)
4 3 (2.29%) 7 (3.57%)
5 0 (0%) 1 (0.51%)
Focal (spotty) lytic necrosis, /apoptosis and focal inflammation
0 0 (0%) 2 (1.02%) 0.001
1 53 (40.46%) 40 (20.41%)
2 54 (41.22%) 107 (54.59%)
3 21 (16.03%) 46 (23.47%)
4 3 (2.29%) 1 (0.51%)
Portal inflammation
0 4 (3.05%) 2 (1.02%) 0.142
1 38 (29.01%) 39 (19.90%)
2 36 (27.48%) 67 (34.18%)
3 49 (37.40%) 74 (37.76%)
4 4 (3.05%) 13 (6.63%)
5 0 (0%) 1 (0.51%)
Viral serology
HBV DNA (log10 IU/ml) 4.67 ± 1.22 7.48 ± 0.82 <0.001
HBeAg positive 36 (27.48%) 110 (56.12%) <0.001
HBsAg (log10 IU/ml) 2.83 ± 0.97 3.67 ± 0.83 <0.001
Serum biochemistry
ALT (IU/L) 161.20 ± 179.34 188.07 ± 168.45 0.175
AST (IU/L) 86.41 ± 89.06 120.77 ± 138.86 0.007
Bilirubin (mg/dL) 1.00 ± 0.50 0.97 ± 0.36 0.559
Albumin (g/dL) 4.58 ± 0.28 4.54 ± 0.39 0.418
Gamma-glutamyltransferase (IU/L) 56.79 ± 42.31 61.58 ± 49.84 0.505
Platelet (1000/mm3) 189.09 ± 49.34 190.23 ± 50.96 0.84
Hemoglobin (g/dL) 15.32 ± 1.34 15.12 ± 1.37 0.26
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annual rate of HBsAg seroclearance has been demon-
strated in a meta-analysis of 13 study cohorts [26]. The
highest rate of HBsAg seroclearance occurred at 50 years
old [26], an age when many patients have already devel-
oped mild or severe liver fibrosis. The negative correla-
tions between fibrosis stages and HBsAg levels has also
been demonstrated in previous univariate analyses [27,
28]. Significantly lower HBsAg levels were found in pa-
tients with ISHAK fibrosis score >1, compared with
those with score ≤ 1 (P < 0.001) [27]. Baseline data from
a multicenter, phase III trial of peginterferon alfa-2a and
a phase IV NEPTUNE trial showed that lower HBsAg
levels were associated with lower PS1 and PS2 scores,
which indicated more severe fibrosis [28].
The necessity of multivariate analysis arises as multiple
factors (age, HBsAg level, fibrosis stage) were shown to
be involved in univariate analyses [27, 28]. Our
systematical evaluation of hematological, histological
and viral serological variables showed that the progres-
sion of liver fibrosis was accompanied by HBsAg reduc-
tion (Table 2, adjusted regression coefficient of “ISHAK
fibrosis stage” = -0.125, P = 0.002), independent of age,
HBV DNA levels, HBeAg positivity, platelet counts and
hemoglobin levels. Age on the other hand was negatively
correlated with HBsAg concentrations only in the uni-
variate analysis but not in the multivariate analysis.
The discrepancy between HBV DNA and HBsAg levels
underlies the reason why HBsAg cannot play compar-
able roles on the estimation of subsequent HCC risks as
what HBV DNA can do (except for patients with very
low levels of HBV DNA). HBV DNA has been estab-
lished as an important predictor of HCC risks [29]. A re-
cent report showed that HBV DNA in general is a better
predictor of HCC than HBsAg [13]. However, in a
Fig. 2 a The scatter plot of HBV DNA and HBsAg levels in the model construction cohort. b Backward stepwise linear regression analysis in patients
with HBV-DNA≤ 6 log10 IU/mL. The x-axis showed the number of variables incorporated in the model, which also equated to the degrees of freedom
in the F-test. The y-axis showed the P values calculated by the F-test. At the beginning, all 16 clinical variables were incorporated into a linear model.
Less relevant variables were progressively removed. At the end of the stepwise process, a linear combination of platelet and HBV DNA levels showed
significant association to HBsAg levels (P = 0.048, degrees of freedom= 2). c Estimated HBsAg levels is a function of HBV DNA levels and platelet counts
in the constructed biphasic model. d A scatter plot of the measured and estimated HBsAg levels in two validation cohorts. Validation cohort 1: patients
with biopsy-included pretreatment evaluations. Validation cohort 2: treatment naïve patients
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HBV DNA (log10 IU/ml) 5.31 ± 1.68 <0.001
HBsAg (log10 IU/ml) 2.79 ± 0.90 <0.001
Hematology
ALT (IU/L) 141.00 ± 124.94 0.087
AST (IU/L) 91.29 ± 83.45 0.277
Bilirubin (mg/dL) 0.90 ± 0.28 0.119
Albumin (g/dL) 4.45 ± 0.28 0.196
Gamma-glutamyltransferase (IU/L) 66.20 ± 65.26 0.626
Platelet (1000/mm3) 179.36 ± 53.17 0.22
Hemoglobin (g/dL) 14.69 ± 1.29 0.032
a Compared with the model-construction cohort
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specific subgroup of HBeAg negative, HBV DNA<
2000 IU/mL patients, HBsAg rather than HBV DNA was
a better predictor [13]. This conclusion was based on a
study population of non-cirrhotic, relatively young pa-
tients (>50% patients were 28–39 years old at the time of
enrolment). Considering the strong effect of fibrosis stages
on the subsequent HCC occurrence [12, 30] and the nega-
tive correlations between HBsAg levels and fibrosis stages
demonstrated here, it was reasonable to say that any po-
tential positive correlations between HBsAg and HCC in-
cidence can only be found in patients with similar fibrosis
status, which however required liver biopsy to be assessed
correctly. The predictive role of HBsAg on HCC reported
in [13] may not be readily extrapolated to elder people
with mild, moderate and severe fibrosis.
A model of HBsAg levels can be constructed straight-
forwardly using the three independent variables (HBV
DNA, fibrosis stages and HBeAg status). This model was
a benchmark in the search for a simpler model with
fewer number of clinical variables. We continued to in-
vestigate patient subgroups stratified by the three inde-
pendent variables. We found that the DNA remained
significantly associated with HBsAg in all strata except
when DNA < 6 log10 IU/mL. A backward stepwise linear
regression analysis in the low-titer subgroup showed
that, after the less relevant variables were removed grad-
ually, platelet counts and HBV DNA remained, and their
combination was synergistically associated with HBsAg
levels. Thus, a biphasic model was constructed using
HBV DNA alone when HBV-DNA > 6 log10 IU/mL, and
platelet levels in conjunction with HBV DNA when
HBV-DNA ≤ 6 log10 IU/mL. This new model is simpler,
with fewer variables, yet the correlation (r = 0.60) is even
higher and the standard deviation of the regression re-
sidual (e = 0.78 IU/mL) is even lower than those of the
three-variable model (r = 0.59 and e = 0.79 IU/mL).
The reduction of platelet counts, i.e. thrombocytopenia,
has been acknowledged to be associated with chronic liver
diseases and cirrhosis [31, 32]. The correlation between
platelet counts and ISHAK fibrosis stages made them both
associated with HBsAg levels in our univariate analysis
(Table 2). When they were both introduced into the multi-
variate analysis, only the ISHAK stage but not the platelet
counts (P = 0.064) remained significantly associated. How-
ever, in the low-titer subgroup when HBV-DNA ≤ 6 log10
IU/mL, platelet counts rather than ISHAK stages were
remained in the backward stepwise regression analysis.
This showed that platelet counts and HBV DNA formed
an effective combination for estimating HBsAg when
HBV-DNA ≤ 6 log10 IU/mL.
Platelets were widely known for their roles in blood
coagulation. In addition to this conventional role, its
antimicrobial roles were gradually being noticed [33].
Platelets can secret chemokine ligand 5 (CCL5) so as to
stimulate the production of megakaryocytes, forming a
positive feedback loop of platelet activation [34]. It can
also secrete hepatocyte growth factor (HGF) so as to
protect against liver fibrosis [35]. The detailed mechan-
ism on the interactions of platelets to the HBV life cycle
warrants further investigations.
The quantitative modeling provided a numerical basis
for our understanding on the relationship between
HBsAg, HBV DNA, age, fibrosis stages and platelet
counts. The estimated HBsAg concentrations correlated
well with the measured HBsAg in the model construc-
tion cohort as well as the two independent validation co-
horts (P ≤ 0.001 in all), supporting the use of the
biphasic model in retrospective studies where the
HBsAg was not measured at previous timepoints and no
stored clinical samples were available. Since quantitative
HBsAg measurement has become more and more avail-
able recently, patients’ HBsAg levels can now be mea-
sured directly without the help of this biphasic model.
Patients in the immune activation and the inactive re-
sidual phases were particularly required for quantitative
HBsAg monitoring, and they were the major population
of our study cohorts. Although we have analyzed a total
of 452 patients, patients in the immune tolerance phases
were not well represented. Therefore, the current ana-
lysis may only be applied to patients in the immune acti-
vation phase onward, but may not be extrapolated to
patients in the immune tolerance phase.
In conclusion, serum HBsAg levels depended on HBV
DNA titers, the liver fibrosis stages, and HBeAg positivity.
Taking into consideration of all the above aspects, we con-
structed a noninvasive, biphasic quantitative model using
two variables, HBV DNA and platelet levels, which can ef-
fectively estimate HBsAg concentrations.
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Table 5 Baseline characteristics of patients in the second








HBV DNA (log10 IU/ml) 6.57 ± 1.78 0.339
HBeAg positive 27 (33.75%) 0.077
HBsAg (log10 IU/ml) 3.05 ± 0.97 0.022
Platelet (1000/mm3) 166.61 ± 64.06 0.003
a Compared with the model-construction cohort
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